Top Stories
Latest Coverage
What Is Synthetic Lethality? How PARP Inhibitors Work in Cancer Treatment
In the field of precision oncology, synthetic lethality is an important concept that has helped shape new approaches ...
In the field of precision oncology, synthetic lethality is an important concept that has helped shape new approaches ...
Global Accessibility of Spinal Muscular Atrophy (SMA) Treatment: Current Status Analysis
Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disorder characterized by the progressive loss of motor...
Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disorder characterized by the progressive loss of motor...
A New Option in Targeted Biologic Therapy: Clinical Insights into Guselkumab Injection
A New Option in Targeted Biologic Therapy: Clinical Insights into Guselkumab Injection
A New Option in Targeted Biologic Therapy: Clinical Insights into Guselkumab Injection
Chinese HER2 Bispecific Antibody + PD-1 Combination Approved in the U.S. for Gastroesophageal Adenocarcinoma, Advancing to the Forefront of Global Oncology
For patients with advanced gastroesophageal adenocarcinoma (GEA), treatment is entering a new phase.
For patients with advanced gastroesophageal adenocarcinoma (GEA), treatment is entering a new phase.
Bone Marrow Protection Throughout Chemotherapy: Trilaciclib Approved for a New Indication, Extending from First-Line to Post-Relapse Treatment
For patients with extensive-stage small cell lung cancer (ES-SCLC), treatment challenges extend beyond the cancer its...
For patients with extensive-stage small cell lung cancer (ES-SCLC), treatment challenges extend beyond the cancer its...
The 30-Year Chemotherapy Standard Faces a New Challenge: China's PD-1 Serplulimab Breaks New Ground in Gastric Cancer Treatment
The 30-Year Chemotherapy Standard Faces a New Challenge: China’s PD-1 Serplulimab Breaks New Ground in Gastric Cancer...
The 30-Year Chemotherapy Standard Faces a New Challenge: China’s PD-1 Serplulimab Breaks New Ground in Gastric Cancer...
